Long Term Response to Therapy of Chronic Anti-Hbe–Positive Hepatitis B Is Poor Independent of Type and Schedule of Interferon

Filippo Oliveri, Teresa Santantonio, G. Bellati, P. Colombatto, Guido Colloredo Mels, Luigi Carriero, Giuseppe Dastoli, Giuseppe Pastore, G. Idéo, Ferruccio Bonino,

The American Journal of Gastroenterology · 1999 · 61 citations · 22 references

Concepts

Abstract

Objective: The response rate to alpha interferon (IFN) of chronic anti-HBe–positive hepatitis B is variable. We studied whether type, dose, and schedule of IFN, and type and frequency of posttreatment monitoring, influence the response rate. Methods: Seventy-two consecutive anti-HBe–positive chronic hepatitis B patients (59 male and 13 female, median age 41 yr) stratified by sex and histology were randomly allocated to three treatment arms. Twenty-seven patients (A) received 10 million units alpha-N1 IFN i.m. t.w. for 24 wk (total dose: 720 million units); 21 (B) received 9 million units alpha-2a IFN i.m. t.w. for 4 wk, followed by 18 million units for 12 wk and 9 million units for 8 wk (972 million units); 24 (C) received 2 alpha-2a IFN courses (9 million units i.m. t.w. for 16 and 12 wk separated by a 6-month interval [756 million units]). Primary response was defined by normal ALT and serum HBV-DNA levels below 10 pg/ml at the end of therapy and sustained response by normal ALT (tested monthly), undetectable HBV-DNA and IgM anti-HBc (<7 I.U. Paul Ehrlich Institute) (tested every 3 months) during the posttreatment follow-up. Results: At the end of treatment, 12, 8, and 13 patients from groups A, B, and C, respectively, were responders. At the 18-month follow-up, two patients in group A and only one in groups B and C maintained the response. Overall, after 34 months (median posttreatment follow-up), three patients were long term responders, whereas three showed a sustained remission after relapse. Conclusions: The rate of long term response to interferon of anti-HBe–positive chronic hepatitis B is poor, independent of IFN type, dose, or schedule; the more stringent the monitoring, the higher the relapse rate.

References

22